Abstract 1515P
Background
PLATFORM is a prospective, open-label, multi-centre, adaptive phase II trial assessing maintenance therapy in patients (pts) with OG adenocarcinoma after platinum-based first-line induction chemotherapy. HER2 -negative pts were randomised 1:1 to surveillance or rucaparib.
Methods
After 18 weeks of platinum-based chemotherapy, pts with response or stable disease were randomised, stratified by performance status, region, and disease extent. Pts in the control arm had 4- weekly surveillance visits vs. receiving rucaparib 600mg twice daily every 28 days to progression, death, or toxicity. Interim analysis target accrual of 61 pts was met, the futility endpoint was 12-week progression free rate (PFR). We also report progression-free survival (PFS) from randomisation to progression or death (pre-specified p-value of 0.025) and toxicity.
Results
125 pts were randomised to the control arm and rucaparib. At data cut-off (28 April 2023) median follow up was 41 months (mo). 59 control and 62 rucaparib pts were evaluable for 12-week PFR; 36% in the control arm and 55% in the rucaparib arm had stable disease (Odds Ratio 2.2, 97.5% CI 1.0-5.1, p = 0.035). 39% of all pts had measurable disease at baseline and no responses were seen in either arm. Median PFS was 2.8 mo in the control arm vs. 4.2 mo in the rucaparib arm (HR 0.70, 97.5% CI 0.46 – 1.08, p = 0.063). The 6 mo PFS rate was 20.4% (97.5% CI 9.9 - 33.5) in the control arm vs. 29.5% (97.5% CI 17.4 – 42.8) in the rucaparib arm but there was no difference in median survival (HR 1.15, 97.5% CI 0.73 – 1.82, p = 0.495). Grade ≥3 treatment related adverse events was 19% in the rucaparib arm and no new safety signals identified.
Conclusions
Interim results showed prolonged disease control in pts receiving maintenance rucaparib after first-line platinum-based chemotherapy. Translational biomarker analysis including homologous recombination deficiency testing may identify a subgroup of pts that could derive additional benefit from maintenance rucaparib.
Clinical trial identification
NCT02678182.
Editorial acknowledgement
Legal entity responsible for the study
D. Cunningham.
Funding
Clovis Oncology.
Disclosure
C.Y.K. Fong: Financial Interests, Institutional, Financially compensated role, Honoraria: BMS. P. Das: Financial Interests, Institutional, Advisory Role: Pfizer, BMS, Eisai, Roche; Financial Interests, Institutional, Other: Janssen, AstraZeneca, Ipsen, MSD, Chugai Pharma. T.S. Waddell: Financial Interests, Institutional, Other, Honoraria, Advisory, Research Funding: Pfizer; Financial Interests, Personal and Institutional, Other, Honoraria, Advisory, Research Funding, Travel/accommodation expenses: Ipsen; Financial Interests, Institutional, Other, Honoraria, Advisory, Research Funding, Travel/accommodation expenses: BMS; Financial Interests, Institutional, Other, Honoraria, travel/accommodation expenses: EUSA Pharma; Financial Interests, Institutional, Other, Advisory, Research Funding,: Roche; Financial Interests, Institutional, Other, Advisory, Research Funding: Merck Sharp & Dohme, Eisai Europe. N. Starling: Financial Interests, Personal, Advisory Board: GSK, Novartis, MSD Oncology, Servier, AstraZeneca, Pfizer, Gilead Sciences; Financial Interests, Personal, Invited Speaker: Clinical Options, Eli Lilly, Pierre Fabre, Amgen, Merck, Novartis, MSD Oncology, GSK, Servier, Seagen; Financial Interests, Institutional, Research Grant, Sept 2017 (24m) Paid to institution research: Merck; Financial Interests, Institutional, Research Grant, Nov 2017 (48m) -Paid to institution research fund: AstraZeneca; Financial Interests, Institutional, Research Grant, Jan 2018 - Paid to institution research fund: Pfizer; Financial Interests, Institutional, Research Grant, July 2018 (36m) Paid to institution research fund: BMS; Financial Interests, Institutional, Research Grant, June 2022: Guardant; Non-Financial Interests, Advisory Role, Ad Board uncompensated.: Guardant. I. Chau: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Eli Lilly, MSD, Roche, Merck, AstraZeneca, OncXerna, Boehringer Ingelheim, Astellas, Incyte, GSK, Sotio, Daiichi Sankyo, Eisai, Taiho, Seagen, Turning Point Therapeutics, Novartis; Financial Interests, Personal, Invited Speaker: Eisai, Eli Lilly, Servier; Financial Interests, Institutional, Coordinating PI: Cilag-Janssen, Eli Lilly. D. Cunningham: Financial Interests, Institutional, Research Funding: Clovis, Eli Lilly, 4SC, Bayer, Celgene, NIHR EME, Leap, Roche; Financial Interests, Institutional, Advisory Role: Ovibio. All other authors have declared no conflicts of interest.
Resources from the same session
1489P - To investigate the differences in efficacy between immunotherapy and combined immunotherapy in elderly patients with non-small cell lung cancer
Presenter: Ye Mao
Session: Poster session 21
1490P - Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
Presenter: Mustafa Bozkurt
Session: Poster session 21
1491P - PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients
Presenter: Jeongmin Seo
Session: Poster session 21
1493P - A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Presenter: Tomasz Jankowski
Session: Poster session 21
1495P - Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Presenter: Ana Baramidze
Session: Poster session 21
1496P - Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Paul Takam Kamga
Session: Poster session 21
1497P - Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
Presenter: Yawen Bin
Session: Poster session 21